February 24, 2022 4:45pm

As Nasdaq reverses higher in a sigh of cell and gene therapy sector oversold relief

Pre-open indications: 2 Hits and 8 Miss

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

What happened today …

The Dow closed UP +92.07 points (+0.28%); the S&P closed UP +63.20 points (+1.50%) while the Nasdaq closed UP +436.10 points (+3.34%)

 

Henry’omics:

the Nasdaq erased earlier losses (-3.5%) and traded meaningfully higher; on Thursday despite the start of Russia's war on Ukraine.

As of Thursday afternoon, stocks were well off their lows of the day. The Dow (-77.11) had been down more than 800 points earlier in the session.

·         Causing global energy prices to jump and sending investors fleeing for the safety of – what’s safe?

 

52-week lows:

  • bluebird bio (BLUE) all-time low of $5.61
  • Homology Medicine (FIXX) all-time low of $2.56
  • Mesoblast (MESO) all-time low of $3.69
  • Adverum Biotechnologies (ADVM) all-time low of $1.27
  • uniQure NV (QURE) all-time low of $15.25
  • Solid BioSciences (SLDB) all-time low of $0.8
  • Fate Therapeutics (FATE) all-time low of $30.44
  • IBB - all-time low of 118.17
  • XBI – 82.02

 

RegMed Investors’ (RMi) pre-open: “the invasion/attack has begun shaking global markets. Volatility is beyond normal, as the 52-week lows are multiplying while Q4 and FY21 earnings don’t help share pricings” …  https://www.regmedinvestors.com/articles/12314

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Thursday opened neutral at 16 up/16 downs, 2 flats and 1 acquired, flipped positive at the mid-day at 25/8, 1 flat 1 acquired, ending with a positive close of 27/7 and 1 acquired;

 

Pre-open Indications: 2 Hits <Biostage (OTCQB: BSTG -$0.67), ReNeuron (RENE.L -$3.00), > 8 Miss < Fate Therapeutics (FATE +$2.12), Sage Therapeutics (SAGE +$2.10), Ionis Pharmaceuticals (IONS +$1.76), Alnylam Pharmaceuticals (ALNY +$5.42), Editas Medicine (EDIT +$1.45), Sangamo Therapeutics (SGMO +$0.33), CRISPR Therapeutics (CRSP +$3.91), UniQure NV (QURE +$0.34)>

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … added (NTLA), (SAGE), (IONS), (SAGE), (SGMO), (VCEL), (EDIT), (SGMO)

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works on Thursday with the shares dumping -$0.67 on 1,259 shares traded after “sudden” volume on Wednesday +$0.20 with 3,070 shares traded after 12 p.m. following Tuesday’s 11 a.m. of 4,225 shares traded popping the stock +$0.70

 

Key Metrics:

Thursday - Sector volume was LOW with 14 of the 27-upside having higher than the 3-month average volume with LOW volume of 3 of 7-downside having higher than the 3-month average volume

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday   the IBB closed up +2.54% and XBI closed up +4.58%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -0.67 points or -2.16% at 30.35

 

Jumping with share pricing momentum (10 of 27):

  • Intellia Therapeutics (NTLA +$7.41 after Wednesday’s -$4.14 and Tuesday’s -$2.33),
  • Vericel (VCEL +$6.70 after Wednesday’s -$1.10 and Tuesday’s -$1.62),
  • Alnylam Pharmaceuticals (ALNY +$5.42 after Wednesday’s +$0.66 and Tuesday’s -$0.69),
  • CRISPR Therapeutics (CRSP +$3.91 after Wednesday’s -$2.41 and Tuesday’s -$2.63),
  • Ultragenyx (RARE +$3.03 after Wednesday’s -$2.13 and Tuesday’s +$0.21),
  • BioLife Solutions (BLFS +$2.23 after Wednesday’s -$0.80 and Tuesday’s -$0.34),
  • Fate Therapeutics (FATE +$2.12 after Wednesday’s -$1.31),
  • Sage Therapeutics (SAGE +$2.10 after Wednesday’s -$1.43),
  • Editas Medicine (EDIT +$1.45 after Wednesday’s -$0.61 and Tuesday’s -$0.19),
  • Global Blood Therapeutics (GBT +$1.42 after Wednesday’s -$2.44 and Tuesday’s -$1.30),

Hammered in today’s market (7 of 7):

  • ReNeuron (RENE.L -$3.00 after Wednesday’s +$1.50 and Tuesday’s -$1.50),
  • Biostage (BSTG -$0.67 after Wednesday’s +$0.20 and Tuesday’s +$0.62),
  • Homology Medicine (FIXX -$0.08 after Wednesday’s +$0.19 and Tuesday’s -$1.26),
  • Cellectis SA (CLLS -$0.03),
  • Pluristem (PSTI -$0.02),
  • Bellicum Pharmaceuticals (BLCM -$0.01 after Wednesday’s +$0.02),
  • Caladrius Biosciences (CLBS -$0.0079)

Closing Flat:

  • 1 - Stemline Therapeutics (STML) – acquired

 

February, Q1/2022:

  • Thursday closed positive with 27 incliner, 7 decliners and 1 acquired
  • Wednesday closed negative with 8 incliner, 26 decliners and 1 acquired
  • Tuesday closed negative with 7 incliners, 25 decliners, 2 flats and 1 acquired
  • Monday (2/21) was a holiday, President’s Day 

 

The BOTTOM LINE: Investors are watching earnings reports this today; as many of those reporting TODAY are showing a positive share pricing.

Q4 and end-of-year earnings are gaming than even I thought.

Earnings’ reporting:

·         Fate therapeutics, Monday, 2/28

·         BioLife Solutions (BLFS), Monday, 2/28

·         Regenxbio (RGNX), Tuesday, 3/1

·         Athersys (ATHX), Tuesday, 3/15

 

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.